

**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

RECEIVED
CENTRAL FAX CENTER
FEB 13 2006

The documents accompanying this telex transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telexed information is strictly prohibited. If you have received this telex in error, please immediately notify us by telephone (collect) to arrange for return of the telexed documents to us.

TO: U.S. Patent Office
Central Facsimile
Processing Facility
Mail Stop AF

FROM: Daniel F. Nesbitt
Hasse & Nesbitt LLC

PHONE: (571) 272-4000
FAX: (571) 273-8300

PHONE: (513) 229-0383
FAX: (513) 229-0683

I, Elaine Willig, hereby certify that the below identified correspondence is being facsimile transmitted to the United States Patent and Trademark Office on February 13, 2006.

Signature: Elaine Willig

Pages being transmitted:

Total No. of Pages including this cover letter: 8

1. Amendment after Final (7 pages).

Application No.: 10/724,532
Filed: 11/29/2003
Inventor: Reed
Attorney Docket No.: GMX-002

COMMENTS:

Attorney Docket No. GMX-002

RECEIVED
CENTRAL FAX CENTER

FEB 13 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Reed, Thomas D. : Examiner: Karen Cochrane Carlson
Serial No: 10/724,532 : Group Art Unit: 1653
Filed: November 29, 2003 : Confirmation No: 3265
Title: SIGNAL FOR TARGETING MOLECULES TO THE
SARCO(ENDO)PLASMIC RETICULUM

AMENDMENT AFTER FINAL OFFICE ACTION PURSUANT TO 37 C.F.R. 1.116

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated December 14, 2005, please enter the following amendments and consider the accompanying remarks.

Amendments to the Claims are reflected in the listing of claims that begin on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.